Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Tenectéplase à faible dose pour le traitement de l'accident vasculaire cérébral aigu chez les patients âgés (DATE-AGING)

1 novembre 2026 mis à jour par: Zhenhua Zhou, Southwest Hospital, China

Efficacité et sécurité du ténectéplase à faible dose pour le traitement de l'accident vasculaire cérébral ischémique aigu chez les patients âgés : une étude prospective, multicentrique, randomisée et contrôlée

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

806

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Anshan, Chine
        • Anshan Changda Hospital
      • Anyang, Chine
        • Anyang People's Hospital
      • Anyang, Chine
        • Huaxian People's Hospital of Henan
      • Baoshan, Chine
        • Baoshan People's Hospital
      • Bijie, Chine
        • People's Hospital of Zhijin County
      • Chongqing, Chine
        • Chongqing University Three Gorges Hospital
      • Chongqing, Chine
        • Chongqing University Jiangjin Hospital
      • Chongqing, Chine
        • Bishan Hospital
      • Chongqing, Chine
        • Chongqing Emergency Medical Center
      • Chongqing, Chine
        • Chongqing University Fuling Hospital
      • Chongqing, Chine
        • Dianjiang People's Hospital OF Chongqing
      • Chongqing, Chine
        • People's Hospital Of Xiushan County
      • Chongqing, Chine
        • The People's Hospital of Dazu Chongqing
      • Chongqing, Chine
        • The People's Hospital of HeChuan, Chongqing
      • Chongqing, Chine
        • The People's Hospital of Rongchang Chongqing
      • Chongqing, Chine
        • The People's Hospital of Tongnan District Chongqing City
      • Chongqing, Chine
        • The Seventh People's Hospital of Chongqing
      • Chongqing, Chine
        • Tongliang Hospital
      • Chongqing, Chine
        • Yunyang County People's Hospital
      • Dali, Chine
        • Dali Bai Autonomous Prefecture People's Hospital
      • Dazhou, Chine
        • Dazhou Central Hospital
      • Deyang, Chine
        • The People's Hospital of Zhongjiang
      • Guang’an, Chine
        • Guang an People's Hospital
      • Guiyang, Chine
        • Guizhou Provincial People's Hospital
      • Guiyang, Chine
        • The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
      • Ha’erbin, Chine
        • The First Affiliated Hospital of Harbin Medical University
      • Hebi, Chine
        • Xunxian People's Hospital
      • Heyuan, Chine
        • Heyuan People's Hospital
      • Huanggang, Chine
        • Qichun People's Hosiptal
      • Jianyang, Chine
        • The People's Hospital Of Jianyang City
      • Laixi, Chine
        • Laixi People's Hospital
      • Leshan, Chine
        • People's Hospital of Leshan
      • Leshan, Chine
        • Leshan Geriatric Specialized Hospital
      • Luoyang, Chine
        • Luoyang Mengjin People's Hospital
      • Nanchong, Chine
        • Nanbu People's Hospital
      • Pujiang, Chine
        • Puyang People's Hospital
      • Pujiang, Chine
        • The People's Hospital of Nan Le Xian
      • Shangqiu, Chine
        • People's Hospital of Ningling County
      • Shangqiu, Chine
        • The First People's Hospital of Shangqiu
      • Shaoyang, Chine
        • The First People ' S Hospital of Shao Yang
      • Shijiazhuang, Chine
        • The People's Hospital of Gaocheng
      • Wuhan, Chine
        • Wuhan Puren Hospital
      • Xiangyang, Chine
        • Xiangyang NO.1 People's Hospital
      • Yibin, Chine
        • The second people's hospital of Yibin
      • Zhumadian, Chine
        • Zhumadian Central Hospital
      • Zhuzhou, Chine
        • Zhuzhou Central Hospital
      • Zigong, Chine
        • Zigong Third People's Hospital
      • Ziyang, Chine
        • Ziyang Central Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Chine, 400038
        • Southwest Hospital, Chongqing, China
    • Heilongjiang
      • Harbin, Heilongjiang, Chine, 150200
        • Wuchang People's Hospital
    • Henan
      • Zhoukou, Henan, Chine, 466300
        • Shenqiu County People's Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

70 ans et plus (Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age ≥ 70 years;
  2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
  3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
  4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
  5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
  6. Informed consent from the patient or surrogate.

Exclusion Criteria:

  1. Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);

  2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to

    • Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
    • Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
    • Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
    • Platelet count of below 100×10^9/ L
    • Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
    • Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
    • Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
    • Neoplasm with increased haemorrhagic risk
    • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
    • History of significant trauma or major surgery within the past 3 months.
    • Any known disorder associated with a significant increased risk of bleeding
  3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);

  4. Blood glucose <2.8 mmol/L or >22.22 mmol/L;

  5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;

  6. Seizure at stroke onset;

  7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;

  8. Participation in other clinical trials within 3 months prior to screening;

  9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Low-Dose Tenecteplase

0.175mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient.

Comparateur actif: Standard-Dose Tenecteplase

0.25mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Délai: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
Délai: At 24 hours

National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.

At 24 hours
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
Délai: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Distribution of Modified Rankin Scale (mRS)
Délai: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Percentage of Participants With Barthel Index Score ≥95
Délai: up to 90 days

The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.

up to 90 days
EQ-5D-5L score
Délai: At Day 90±7 days

Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life)

At Day 90±7 days
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
Délai: up to 36 hours

sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline.

up to 36 hours
All-cause mortality
Délai: up to 90 days

All-cause mortality at 90 days

up to 90 days
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
Délai: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 décembre 2025

Achèvement primaire (Réel)

1 novembre 2026

Achèvement de l'étude (Réel)

1 novembre 2026

Dates d'inscription aux études

Première soumission

21 novembre 2025

Première soumission répondant aux critères de contrôle qualité

7 décembre 2025

Première publication (Réel)

19 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

1 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2025IITDA10

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner